Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities

NCT02406274 | Completed

• 1 other identifier: 15-053
• Study Type: interventional
• Target: 249
• Locations: 1 country
• Sites: 1

Brief Summary

Contrast Enhanced Spectral Mammography (CESM) is an advanced form of mammography which is performed after injection of contrast or dye into a vein in the arm. This dye is the same dye that is used for CT scans. This type of mammogram includes a regular mammogram as well as additional pictures with the dye. This particular study is being done to determine if by adding the dye in the veins the investigators are better able to identify the cause of the lump than if they just did the regular mammogram alone.

Conditions

Breast Abnormalities

Keywords

Mammography; Contrast Enhanced Spectral Mammography; Palpable Breast Abnormalities; 15-053

Outcome Measures

Primary Outcomes (1)

• positive predictive value

  (PPV) will be defined using three distinct definitions: (1) PPV1 is the proportion of women with a positive assessment who had a cancer diagnosis in the follow-up period. (2) PPV2 is the proportion of women with a recommendation for biopsy who had a cancer diagnosis in the follow-up period. (3) PPV3 is the proportion of women with a biopsy recommendation and a biopsy performed within 1 year who had a cancer diagnosis in the follow-up period. Negative predictive value (NPV) is the proportion of women with a negative assessment who did not have a cancer diagnosis.

  1 year

Study Arms (1)

Contrast Enhanced Spectral Mammography

EXPERIMENTAL

Other: Contrast Enhanced Spectral Mammography (CESM)

Interventions

Contrast Enhanced Spectral Mammography (CESM) OTHER

Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.

Contrast Enhanced Spectral Mammography

Eligibility Criteria

• Age: 25 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Women presenting for mammographic evaluation of an undiagnosed palpable mass found either by self examination and/or examination by referring physician

You may not qualify if:

• Age \< 25 years old
• Male patients
• Pregnant or lactating patients
• Patients with allergy to iodinated contrast
• Patients with a history of renal disease or patients over 70 with a creatinine \> 1.3. Creatinine must have been done within the last 12 weeks.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

Study Officials

• Maxine Jochelson, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 30, 2015
• First Posted: April 2, 2015
• Study Start: March 1, 2015
• Primary Completion: June 27, 2024
• Study Completion: June 27, 2024
• Last Updated: June 28, 2024

Record last verified: 2024-06

Locations

US (1)